Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF), a diversified molecular diagnostics company, will begin trading of its American Depository Shares (ADS) on NASDAQ on December 14, 2023.
To ensure GTG’s securities trade on the same basis, on the same date, the company’s ordinary shares will begin trading on the ASX on a consolidated basis, on the same date.
This follows the company’s shareholders approving a 100:1 share consolidation at Genetic Technologies’ 2023 AGM.
Genetic Technologies is a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases through its geneType and EasyDNA brands.
The company offers cancer predictive testing and assessment tools to help physicians improve health outcomes for people around the world.
GTG has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals.